Quetiapine in patients with borderline personality disorder and psychosis: a case series
| Autor: | Lars Friege, Torsten Gruettert |
|---|---|
| Rok vydání: | 2005 |
| Předmět: | |
| Zdroj: | International Journal of Psychiatry in Clinical Practice. 9:180-186 |
| ISSN: | 1471-1788 1365-1501 |
| DOI: | 10.1080/13651500510029048 |
| Popis: | Objective Atypical antipsychotics appear to be effective and well tolerated in the treatment of borderline personality disorder. One such agent, quetiapine ("Seroquel"), has a favourable side-effect profile and may be of value in acute and chronic treatment of this disorder. Methods In this case series, 12 outpatients with psychotic disorders meeting ICD-10, DSM-IV and DIB-R criteria for borderline personality disorder were treated with quetiapine monotherapy 300-750 mg/day. The CGI-S and the GAS assessed changes in symptom severity and global functioning, whereas the BIS, the HAM-D and the SCL-90-IX scales assessed change of psychotic symptoms and/or borderline personality disorder core symptomatology over time. Patients were evaluated at baseline and at 4 and 12 weeks after treatment. Statistical analyses included Page's trend test and Wilcoxon tests. Results All patients completed the 12-week study. The mean quetiapine dose was 537.5±18.9 mg/day. For all efficacy measures (with the exception of HAM-D), significant improvements were observed as early as Week 4 (P0.01) and at endpoint (P0.05). Conclusion Quetiapine relieved symptoms of psychosis, reduced impulsivity or depressed mood and improved global functioning in patients with borderline personality disorder and psychosis. Quetiapine was well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|